Tumor-associated antigen presentation via major histocompatibility complex class II molecule

Tumor-associated antigen presentation via major histocompatibility complex (MHC) class II molecules refers to the process by which tumor antigens (tumor-associated antigens, TAAs) are processed and presented by MHC class II molecules on the cell surface, primarily by professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells, and occasionally by tumor cells themselves if induced by cytokines like interferon-gamma. This presentation pathway is essential for the activation of CD4+ T helper cells, which then contribute to anti-tumor immune responses. While normally restricted to exogenous (extracellular) antigens, endogenous tumoral proteins and neoantigens can access the MHC-II pathway through processes like autophagy or direct uptake. Aberrant or suppressed MHC-II antigen presentation in tumors is a mechanism of immune evasion, and strategies that restore or enhance this pathway are being explored as avenues for cancer immunotherapy[1][3][5][7]. **Note:** - This is not a single canonical target molecule or receptor but rather a complex process encompassing multiple molecules (MHC class II, accessory proteins, transcriptional regulators like CIITA, etc.)[3][4]. - Individual molecules such as "Major histocompatibility complex class II molecule" (MHC-II) are valid targets, whereas this entry instead describes a functional pathway, making it **not a strict molecular or receptor target** and thus "is_incorrect" is set to true.

Other names

Tumor antigen presentation on MHC class IITumor MHC class II antigen presentationTumor-associated antigen presentation (MHC-II pathway)

Immunomodulation (e.g., upregulation of MHC class II expression, manipulation of antigen processing machinery)[5][3] - Enhancement of tumor immunogenicity - Immune checkpoint inhibition (by promoting or restoring antigen presentation to T cells)[5]